Subscribe to our Newsletters !!
In the era of changing pharmaceutical innovation p
The pharmaceutical sector is on the cusp of a new
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
A few months b Pharma News
A few months b
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
The pharmaceutical sector is on the cusp of a new era. Microbial biotechnology is transforming the development of next-generation drugs and biologics. Pumps in next-generation drug development are no longer just treated as a source of infection and have become invaluable partners in the development of next-generation drugs.
Microbial-engineered life-saving therapeutics and microbiome-engineered life-altering therapeutics innovations redefined the future of pharmaceutical innovations and investments.
Research in microbial biotechnology and drug development has shifted away from a predominant reliance on synthetic chemistry. Now, as a result of synthetic biology and genomics a number of microorganisms are able to synthesize complex chemotherapeutics more efficiently. Drug development in a sustainably and economically viable way.
Research, Actinomycetes, fungi and bacteria have been the backbone in the development of antibiotics. Recent advancements in genome mining and CRISPR-Cas systems have opened previously “silent” microbial pathways.
Natural product rediscovery is possible because of advances in synthetic microbial biotechnology. Companies like ginkgo bioworks and synlogic are developing therapeutics with more microbial systems in engineered designs to lessen the adverse effects of drugs.
The demand for biologics and biosimilars continues to increase, and microbes are at the center of this increase. Strains of E. coli, Pichia pastoris, and Bacillus subtilis are used as biofactories for the production of hormones, monoclonal antibodies, and vaccines.
Microbial fermentation is scalable, sustainable, and offers less reliance on materials of animal origin. The precision fermentation coupled with metabolic engineering leaps lets firms manufacture highly pure biologics with extraordinary uniformity and consistency—signifying advancement in green biomanufacturing.
The most exciting innovation frontier is within us. Gut microbiome is linked to one’s immune system, mental health, and even to other unknown maladies. This is the foundation for Live Biotherapeutic Products (LBPs), a whole new class of therapeutics.
Microbiome research has attracted significant investment from both start-ups and large pharmaceutical companies. For instance, Flagship Pioneering’s venture Seres Therapeutics offers microbiome therapies for recurrent Clostridioides difficile infection that symptomatically treats disease. This innovation offers hope of restoring microbial balance. The potential for other chronic diseases like cancer, diabetes, and even neurological disorders is enormous.
Interest from venture capitalists and pharmaceutical companies alike is helping to push the global microbial biotechnology market to over USD 60 billion by 2030, as predicted by market analysts. Such growth is attracting government support, evidenced by funding programs that merge academic research to market outcomes.
There is good reason for the interest: microbial platforms provide cost efficient, quick research and development, and maintain sustainable manufacturing processes. Given the global trend of biologically based products, the life science market is primarily focused on the growth potential of these products.
There is no question that microbial biotechnology is promising, but it is not without barriers that in part include regulations and issues involving scaling. Ultimately, it is the safety, quality, consistency and therapeutic claiming that will be the primary concerns that must be addressed. Fortunately, the combination of bioinformatics, AI-aided design, and the throughput screening technologies will solve the problems described. Symbiotic pharmaceuticals will be the future. The incorporation of microbial systems into primary drug development processes will be a testimony to the waste elimination paradigm of the future met with prospective sustainable drug development. As capital is allocated to microbial innovation, it will provide a world of new possibilities for the pharmaceutical industry and medicines of the future.
Microbes have moved beyond the realm of laboratory study to become partners in progress at the boardroom level. The combination of microbial innovation with the aspirations of the pharmaceutical industry is beginning to open pathways that were previously thought to be impossible.
